For type 2 diabetes patients who require an injectable drug, GLP-1-based drugs are preferred over insulin

That's a pretty big change:Diabetes Guidelines Updated: For patients with type 2 diabetes who require an injectable drug, a glucagon-like peptide 1 receptor agonist is preferred over insulin.https://buff.ly/2T0KowcGlucagon-like peptide-1 (GLP-1)-based therapies (eg, GLP-1 receptor agonists, dipeptidyl peptidase-4 [DPP-4] inhibitors) affect glucose control throughseveral mechanisms, including:- enhancement of glucose-dependent insulin secretion- slowed gastric emptying- reduction of postprandial glucagon and food intakeThese agents do not usually cause hypoglycemia.Short-acting GLP-1 receptor agonists have an effect on postprandial hyperglycemia and gastric emptying:-Exenatide twice daily. Exendin-4 is a naturally occurring component of the Gila monster lizard saliva and shares 53 percent sequence identity with GLP-1. Exenatide (half-life 2.4 hours) is synthetic exendin-4. Brand Names: Bydureon; Byetta Pen.-Lixisenatide is a GLP-1 receptor agonist that shares some structural elements with exendin-4. Compared with native GLP-1, it has a prolonged half-life (2.7 to 4.3 hours). Brand Names: Adlyxin.Long-acting GLP-1 receptor agonists have a greater resistance to dipeptidyl peptidase-4 (DPP-4) degradation. They activate the GLP-1 receptor continuously and have a prolonged half-life, thus allowing for once-daily and even once-weekly subcutaneous injection. They have a marked effect on fasting glucose.-Exenatide once weekly is a sustained-release formulation of the short-acting subc...
Source: Clinical Cases and Images - Blog - Category: Universities & Medical Training Tags: Diabetes Source Type: blogs